The landmark CANTOS trial evaluated the use of canakinumab, a monoclonal antibody targeting interleukin 1β, in 10 061 patients with previous myocardial infarction who had high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or higher.¹ Interleukin 1β has multiple potential mechanisms that contribute to the pathogenesis of atherothrombotic cardiovascular disease.² Induction of interleukin 6 leads to the release of acute phase reactants including hsCRP. Thus, hsCRP serves as a surrogate marker of the overall inflammatory milieu,² often in situations where patients have multiple co-morbidities,³ with a cumulative dose-response indicating a higher risk.

中文翻译：

---

高敏C反应蛋白的治疗浓度

这项具有里程碑意义的CANTOS试验评估了针对10 061例既往有心肌梗塞的高敏感度C反应蛋白（hsCRP）浓度为2 mg / L或更高的患者，针对白介素1β的单克隆抗体canakinumab的使用。¹白细胞介素1β具有多种潜在机制，可导致动脉粥样硬化血栓性心血管疾病的发病机理。²白介素6的诱导导致包括hsCRP在内的急性期反应物的释放。因此，C反应蛋白作为整体炎症环境的替代标记物，²经常在的情况下的患者有多个共病，³，累积剂量-反应指示的更高的风险。